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CRISPR/CasMouse transgenesis has been instrumental in determining the function of genes in thepathophysiology of human
diseases and modiﬁcation of genes by homologous recombination in mouse embryonic stem cells remains a
widely used technology. However, this approach harbors a number of disadvantages, as it is time-consuming
and quite laborious. Over the last decade a number of new genome editing technologies have been developed,
including zincﬁnger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered reg-
ularly interspaced short palindromic repeats/CRISPR-associated (CRISPR/Cas). These systems are characterized
by a designed DNA binding protein or RNA sequence fused or co-expressed with a non-speciﬁc endonuclease,
respectively. The engineered DNA binding protein or RNA sequence guides the nuclease to a speciﬁc target se-
quence in the genome to induce a double strand break. The subsequent activation of the DNA repair machinery
then enables the introduction of gene modiﬁcations at the target site, such as gene disruption, correction or in-
sertion. Nuclease-mediated genome editing has numerous advantages over conventional gene targeting, includ-
ing increased efﬁciency in gene editing, reduced generation time of mutant mice, and the ability to mutagenize
multiple genes simultaneously. Although nuclease-driven modiﬁcations in the genome are a powerful tool to
generate mutant mice, there are concerns about off-target cleavage, especially when using the CRISPR/Cas sys-
tem.Here,wedescribe the basic principles of these new strategies inmouse genomemanipulation, their inherent
advantages, and their potential disadvantages compared to current technologies used to study gene function in
mouse models. This article is part of a Special Issue entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Genome-wide association studies (GWAS) have been instrumental
in the identiﬁcation of single nucleotide polymorphisms (SNP)s associ-
ated with complex human diseases. The number of genetic associations
has been steadily increasing each year since the introduction of this
approach in 2005. Genomic regions marked by speciﬁc SNPs have
attracted the attention of many researchers to potentially identifying
the causal variant and understanding the pathophysiology of the
disease [1,2]. These genomic regions can contain either protein-coding
(direct protein variants) or non-coding regions that might regulateaced short palindromic repeats/
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Sluis).the expression of genes. However, discovering the causal variant and re-
vealing the underlying biologicalmechanism of the associated disease is
still a complicated process. For a number of reasons, the mouse is the
most valuable and readily accessible animal model as a biological source
to study genes within the candidate loci. The genome of the mouse has
been fully sequenced, and most of the genes (~99%) in human are also
present in mice. Mice are highly comparable to humans with respect
to organs, tissues and physiological systems, enabling the study of
gene-environment interactions in the whole organism. Furthermore,
mice are easy to breed with a relatively short generation time, are
small, and can be housed together, thereby keeping the costs relatively
low. The discovery of gene editing via homologous recombination in
mouse embryonic stem (ES) cells has further spurred the use of mice
over other animal models [3–5]. Here, we will give an overview of the
various tools for gene modiﬁcation that have been developed during
the last decades. Additionally, we will focus on new developments in
mouse technology and the advantages these have over existing technol-
ogies to translate genetic ﬁndings into functional biological assessments.
2. Gene editing by homologous recombination
Most human diseases are studied from a candidate gene approach
that has been identiﬁed by linkage or association studies, or deep
1943T. Wijshake et al. / Biochimica et Biophysica Acta 1842 (2014) 1942–1950sequencing approaches [6,7]. Although human diseases are usually very
complex, typically involving gene-gene and/or gene-environment in-
teractions, the most straightforward and commonly used method to
study the function of candidate genes is by modifying these genes in
mice. The development of gene targeting technology in ES cells was a
major breakthrough that led to the generation of numerous mutant
mousemodels. The techniquemakes use of homologous recombination
to mutagenize the genome in ES cells, which creates a deletion,
insertion, or point mutation [8]. However, ~30% of all knockouts are
embryonic or early postnatal lethal, which led to the development
of other mutagenesis strategies, like Dre/Rox, Flp/Frt and the most
widely used Cre/LoxP system. These systems provide the possibility of
generating a tissue/cell-speciﬁc gene knockout (discussed below)
[9–11]. Cre/LoxP is a site-speciﬁc recombination system that was dis-
covered in bacteriophage P1 [11,12]. Cre recombinase drives recombi-
nation between two DNA recognition sites of 34 bp, also known as
LoxP sites [8]. Genomic regions that are ﬂanked by loxP sites in the
same orientation, also termed a “ﬂoxed allele”, will be excised in cells
expressing Cre recombinase [13].
In general, this mutagenesis approach is commonly used if the gene
of interest is vital for normal embryogenesis or if there is a necessity to
investigate the function of the gene in a tissue/cell-speciﬁc context.
Mice carrying the ﬂoxed alleles will be crossedwith amouse strain con-
taining a transgene encoding the Cre recombinase under the control of a
tissue-speciﬁc promoter, which results in conditional/tissue-speciﬁc
knockout mice [14–16]. Over the last two decades, numerous, tissue-
speciﬁc, Cre-driver lines have been developed. However, some
drawbacks in the Cre/LoxP system have also started to emerge, which
was recently extensively reviewed [16,17]. One major concern is the
tissue-speciﬁcity of the chosen promoter that drives the Cre transgene.
Expression of various genes assumed to be restricted to a speciﬁc tissue
or cell type are actually expressed in multiple tissues/cells [16–18]. An
additional problem is that Cre recombinase transgenic mice can have
too high or low Cre activity, leading to toxicity or inefﬁcient deletion
of the gene, respectively [16]. Furthermore, Cre recombinase itself can
also cause unwanted side-effects, such as random recombination, re-
duced proliferation and increased apoptosis, supporting the need to in-
clude the Cre recombinase transgenic mice as an additional control in
the study design [16].
Another elegant method to examine gene function in a more physi-
ological fashion is by engineering mice with reduced expression of the
gene of interest. This can be accomplished by creating a hypomorphic
allele that results in the expression of only a fraction of the normal pro-
tein levels. Combining a hypomorphic allele with either a wild-type,
knockout, or hypomorphic allele enables generation of a series of mice
with a gradual reduction in protein levels [19]. For example, this strate-
gy has successfully been used to study the mitotic checkpoint proteins
BubR1 and Bub1. Complete ablation of these genes results in embryonic
lethality, but mice with reduced protein levels are born healthy and
show an overt phenotype later in life [20,21]. The strategies to generate
a hypomorphic allele have recently been described in detail [19,22].
Although gene editing by homologous recombination in ES cells is
still themostwidely used strategy to generatemutantmice the efﬁcien-
cy of homologous recombination is very low. Therefore this genetic
editing method has to be performed in ES cells ﬁrst instead of in the
mousedirectly. In addition, the availability of ES cells fromdifferent spe-
cies is limited. All this combined has led to the development of new
techniques, such as ZFNs, TALENs and CRISPR/Cas that harbor signiﬁ-
cantly improved efﬁciencies in gene editing [23–25]. The basic princi-
ples and advantages of these technologies will be discussed in the
following sections.
3. Zinc ﬁnger nucleases
Zinc ﬁnger nucleases (ZFNs) facilitate genetic modiﬁcation through
the introduction of a double strand break (DSB) in a DNA sequence ofinterest. Subsequent DNA break repair then enables the introduction
of the desired modiﬁcation, which is discussed in detail below [26,27].
The DSB is produced by a ZFN, which is a sequence-speciﬁc endonucle-
ase that can be designed to cleave at a precise DNA sequence [27]. A ZFN
consists of a varying number of zinc ﬁnger proteins (ZFPs) or Cys2His2
ﬁngers which are usually fused to the nuclease domain of FokI, a restric-
tion enzyme that cleaves non-speciﬁc DNA sequences [27–31] (Fig. 1A).
Each ZFP is able to recognize a distinct three-base-pair DNA sequence
and a typical ZFN consists of 3–6 fused zinc ﬁnger proteins. Optimal
FokI cleavage by ZFNs requires two independent ZFNs to bind on oppo-
site DNA strands in the appropriate orientation and at the correct
distance from each other [27,32] (Fig. 1A).
The introduction of a DSB by ZFNs at a predeﬁned DNA locus pro-
vokes activation of a conserved DNA repair pathway, namely non-
homologous end joining (NHEJ) or homology-directed repair (HDR)
[33–35] (Fig. 1B). Inmost cases theDSB is repaired by theNHEJ pathway,
which efﬁciently ligates the two broken ends. However, the NHEJ path-
way is error-prone and the repair can result in small deletions and/or in-
sertions (indels), which can lead to gene disruption [27,33] (Fig. 1B).
Gene inactivationwas initially applied by expression of two ZFNs direct-
ed against the yellow gene in the larvae of Drosophila melanogaster,
which resulted in germline mutations [36,37]. Subsequently, ZFN tech-
nology has successfully been applied to mutagenize genes in various or-
ganisms, including zebraﬁsh, rats and mice with varying frequency [23,
38–42]. For example,microinjection of engineered ZFNs in embryoswas
used to generateMrd1a and Tnfrsf9 knockout mice, respectively [23,42].
In addition to single gene disruption, ZFN technology has also been used
to target two or three genes simultaneously inmammalian cells [43,44].
Furthermore, larger deletions, translocations, duplications and inver-
sions can be introduced with ZFN [44–48].
HDR enables the introduction of single nucleotide changes (gene
correction) after DSB induction by ZNF upon simultaneous delivery of
a donor DNA repair template, which contains homology arms ﬂanking
the site of alteration [37,49,50] (Fig. 1B). This opens the possibility to
study the functional consequences of human disease-associated point
mutations in the preferred cells and/or model organisms [23,51–54].
In addition, this approach can be used to engineer larger modiﬁcations,
including insertions of loxP sites, ﬂuorescent proteins, antibiotic resis-
tance markers, or other tags [52,55–59]. There are limitations to gene
correction and gene addition via HDR: the need for co-delivery of a de-
signedDNAdonor template togetherwith a speciﬁc-ZFN, and the strong
preference of a cell for NHEJ over HDR-mediated repair of the DSB. Pos-
sible solutions are either to use ZFN nickases or a vector carrying multi-
ple copies of linear donor fragments, which both increase HDR-driven
genome editing while reducing unwanted mutations caused by NHEJ
[60–63].
Importantly, ZFN-mediated gene modiﬁcation has great therapeutic
potential. ZFN has the advantage over known knockdown or blocking
strategies because it is efﬁcient and persistent, which could avoid the
need for life-long treatment. For example, independent studies have
shown that disruption of the CCR5 and CXCR4 gene, which encode HIV
co-receptors, protects against HIV-1 infection in vitro and in vivo.
Based on the CCR5 studies, ZFN-mediated therapies for HIV have been
designed and are currently being used in Phase 2 clinical trials [27,
64–68]. ZFN-induced HDR can also be exploited to correct genetic
disease-causingmutations, as demonstrated in human induced pluripo-
tent stem (iPS) cells carryingmutations underlying Parkinson’s disease,
α1-antitrypsin deﬁciency, or sickle-cell anemia [69–71]. Furthermore,
ZFN-driven gene correction has been demonstrated to be effective in a
mouse model of hemophilia, raising the possibility of in vivo genome
editing by ZFN as a strategy for the treatment of genetic diseases [72].
The risk for potential off-target DNA cleavage when using ZFN technol-
ogy raises some concerns. Increased ZFN speciﬁcity and simultaneous
reduction of off-target cleavage can be achieved by linking more ZFPs
in a ZFN, optimizing the orientation of protein-DNA interaction and
using a heterodimer ZFN pair [51,73]. Although some reports have
A
T
G
C
T T T T T
T
TTC C G A A GG A C
C
G G GGG
C
CCCC
AA
AAA
G
A
G G G GGT T T TTTC CC CA A A AAC C G
T
A
FokI
FokI
ZF ZF ZF
ZFZFZF
5’
3’
3’
5’
A
B
ZFN cleavage
Non-Homologous
End Joining
Gene disruption
Add DNA donor
Homology-Directed
Repair
Gene correction
Gene addition
Fig. 1.Overview of ZFNs. A. ZFN consisting of three zinc ﬁnger proteins fused to the catalytic domain of FokI restriction enzyme. Each zinc ﬁnger protein is able to bind to three nucleotides
and can guide the ZFN to a speciﬁc target site in the genome. Two ZFNs targeting a speciﬁc sequence on opposite sides of genomic DNA are necessary to allow dimerization of two non-
speciﬁc FokI nucleases. B. Dimerization of two FokI enzymes induces a DSB at the target site. Subsequent DNA-repair by the erroneous NHEJ pathway can introduce the desired genomic
modiﬁcation, like gene disruption. Alternatively, the addition of a DNA repair template can facilitate HDR-mediated genome editing and result in gene correction or addition. ZF = zinc
ﬁnger protein.
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[50,74]. A systematic evolution of ligands by exponential enrichment
(SELEX) protocol and unbiased genome-wide analysis can be utilized
to determine the speciﬁcity for ZFP DNA binding and rank the risk of
potential off-target sites [75,76]. Combination of the SELEX protocol
with ultradeep sequencing conﬁrmed the high ZFN speciﬁcity for the
target site in CCR5 and only identiﬁed rare off-target sites with low
frequency [64].
There are currently a number of methods to fuse ZFPs with each
other to generate new ZFNs, including modular assembly [77],
Oligomerized Pool ENgineering (OPEN) system [78], a bacterial
one-hybrid system [39], two ﬁnger modules [79,80] and context-
dependent assembly [81]. However, the construction of ZFNs is
challenging for non-specialist laboratories, especially with the
bacterial one-hybrid and OPEN systems. Furthermore, most ZFNs
fail to modify the gene of interest in vivo. This can be caused by either
speciﬁcity issues through identical or very similar sequences in the ge-
nome or by the chromatin structure at the site of interest that prevents
ZFN binding [27]. Current studies are focusing on improving the
design and construction of ZFNs, increasing their speciﬁcity and thereby
reducing off-target cleavage. In conclusion, ZFN technology appears to
be a promisingmutagenesis tool for generatingmutant animals, includ-
ing mice, and may have the potential to be used in therapeutic
applications.4. Transcription activator-like effector nucleases (TALENs)
Transcription activator-like effectors (TALEs) from plant pathogenic
Xanthomas are virulence factors secreted via the type III system that can
bind to host DNA and activate expression of effector-speciﬁc host genes
[82,83]. TALEs contain a characteristic central domain of DNA-binding
tandem repeats, a nuclear localization signal, and a C-terminal tran-
scriptional activation domain [84–86]. A typical repeat is 33–35 amino
acids in length and contains two hypervariable amino acid residues at
positions 12 and 13, known as the “repeat variable di-residue” (RVD)
(Fig. 2A). Two studies discovered that an RVD is able to recognize one
speciﬁc DNA base pair and that sequential repeats match consecutive
DNA sequences. They demonstrated that target DNA speciﬁcity is
based on the simple code of the RVDs, which thus enables prediction
of target DNA sequences [82,83]. Nucleotide speciﬁcity of repeats was
shown for RVDs encodingNN, NI, HD andNG for recognition of guanine,
adenine, cytosine and thymine, respectively [83,87]. The ﬁrst successful
generation of TALE nucleases (TALENs) was reported in two studies, in
which they fused either native or modiﬁed TALEs to the catalytic do-
main of the FokI restriction enzyme. These native and custom-made
TALEN fusions were able to induce target-speciﬁc double-strand cleav-
age in yeast [88,89]. The essential TALEN architecture necessary for efﬁ-
cient genome editing in human cells was determined by linking TALE
truncation variants to the catalytic domain of FokI. This approach
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Fig. 2.A. Representation of a TALE characterized by anN-terminal domain, a central DNA-binding repeat domain and a C-terminal domain containing two nuclear localization signals (NLS)
and the activation domain (AD). A typical repeat is 34 amino acids in length and contains twohypervariable amino acids at position 12 and 13 known as the RVD (highlighted in red). Each
RVD is able to recognize one speciﬁc DNA base pair and serial repeats recognize speciﬁc DNA sequence and activate expression of speciﬁc effector host genes through the activation do-
main. B. Depiction of a TALEN. A TALEN containing 12 speciﬁc repeats that correspond to binding either thymine (red), cytosine (green), adenine (blue) or guanine (yellow) fused to the
nuclease domain of FokI. Simultaneous binding of a TALEN pair on opposite strands of DNA ﬂanking the target site facilitates dimerization of FokI and results in a TALEN-induced DSB.
Ensuing DNA repair by the NHEJ or HDR pathway can be exploited to introduce the desired genetic modiﬁcation.
1945T. Wijshake et al. / Biochimica et Biophysica Acta 1842 (2014) 1942–1950revealed that the N-terminal 152 residues were dispensable and
TALE variants containing 28 or 63 of the 278 original C-terminal
amino acids were sufﬁcient to drive efﬁcient gene modiﬁcations of
two endogenous genes. Furthermore, they demonstrated that the
correct distance between the TALEN pair is essential for successful
cleavage [87].
Similarly to ZFNs, TALENs enable genetic modiﬁcation through
induction of a double strand break (DSB) in a DNA target sequence.
Ensuing DNA break repair by either the NHEJ or the HDR-mediated
pathway can be exploited to introduce the desired modiﬁcation
(e.g. gene disruption, gene correction or gene insertion) [24] (Fig. 2B).
TALENs have been utilized to efﬁciently introduce targeted genetic
modiﬁcations in a number of model organisms, including Drosophila
melanogaster [90], zebraﬁsh [91–93], rat [94], pig and cow [95], rhesus
and cynomolgus monkeys [96]. Most of these studies used TALENs to
generate an NHEJ-mediated knockout animal, but two studies reported
the use of two TALENpairs to generate larger deletions and inversions in
livestock ﬁbroblasts and zebraﬁsh [95,97]. Two designed TALEN pairs
were also able to induce cancer-relevant translocations found in ana-
plastic large cell lymphoma [98]. Injection of TALEN mRNA speciﬁc for
exon 2 of Pibf1 gene and for exon 1 of Sepw1 gene into the cytoplasm
of mouse pronuclear-stage embryos resulted in founders carrying
null mutations in the Pibf1 and Sepw1 gene. All mutations observed in
F0 mice were transmitted through the germline [99]. Increasing
the amount of mRNA injected can produce a higher mutation rate andbi-allelic mutation frequency, but this can also result in fewer mutant
mice due to the toxicity of high doses of mRNA [99]. Similar approaches
using microinjection of TALEN mRNA targeting genes in mouse oocytes
and zygotes have been successful in engineering knockout mice
[100–105]. Exploitation of TALEN-mediated genome editing in mouse
ES cells resulted in mice with targeted gene disruptions and insertions
in two Y chromosome-linked genes, which was previously impossible
with conventional gene-targeting technology [106]. HDR-driven inser-
tionwas introduced by simultaneous delivery of TALENwith a designed
single-stranded DNA repair template in human pluripotent stem
cells, somatic cells, zebraﬁsh and rats [87,93,107–109]. For example,
Hermansky-Pudlak syndrome and amyotrophic lateral sclerosis mis-
sense mutations in the Rab38 and Fus genes, respectively, were intro-
duced in mice [102,110]. Subsequently, TALEN-driven HDR was
applied to correct the introduced mutation in the Rab38 gene [110].
TALENs have also been successful in generating human stem cell-
based disease models, and restoring expression of functional Dystro-
phin in cells from Duchenne muscular dystrophy patients [111,112].
New applications include TALEN-mediated generation of a conditional
mouse model, human pluripotent stem cell line with conditional
transgene expression, knockout of human microRNA genes and single
base-editing of an intergenic region upstream of the BUB1 gene
[113–116]. Furthermore, TALE-DNA binding domains enables reversible
modulation of mammalian endogenous gene expression and targeted
epigenetic chromatin modiﬁcations [117–119].
1946 T. Wijshake et al. / Biochimica et Biophysica Acta 1842 (2014) 1942–1950Similar to ZFNs, a concern of genome editing by TALENs is the
occurrence of off-target modiﬁcations. Extensive analysis of known
TALEN/DNA cleavage proﬁles determined speciﬁcity scoring of each
RVD/nucleotide association, which can be used as a guide in the design
of TALENs [120]. TALENs can only tolerate limited position-dependent
mismatches to keep detectable cleavage activity in vivo, demonstrating
its high speciﬁcity [120]. In addition, newly synthesized TALEN variants
have shown equal on-target cleavage activity and on average ten times
lower off-target cleavage activity in human cells [121].
Currently, a number of methods have been developed for engineer-
ing of TALE repeats [24]: Standard cloning-based [91,92], “Golden Gate”
cloning [122–124], iterative capped assembly [125], and the fast
ligation-based automatable solid-phase high-throughput (FLASH) sys-
tem [126], which has the advantage that construction is rapid, cheap
and large number assemblies are feasible. More recentmethods include
ligation-independent cloning [127] and fairyTALE [128], which enable
the high-throughput assembly of TALE repeats.
5. Clustered regularly interspaced short palindromic repeats/
CRISPR-associated (CRISPR/Cas) system
In addition to TALENs and ZFNs, the CRISPR/Cas system has recently
been introduced as an efﬁcient and versatile tool for genome editing.
CRISPR is an essential part of the immune system of bacteria and ar-
chaea directed against foreign nucleic acids [129–131]. Upon challenge
with a viral or plasmid pathogen, bacteria and archaea integrate short
fragments of foreign DNA (protospacers) into their own chromosomes
at the proximal end of a repetitive element known as the CRISPR
locus/array [129–132].
The CRISPR locus is characterized by a series of direct repeats of ap-
proximately 20–50 base pairs separated by unique spacers of similar
length [130,131]. Transcription of the CRISPR loci into precursor
CRISPR RNA (pre-crRNA) is followed by enzymatic cleavage, which re-
sults in short crRNAs that can bind with complementary sequences of
foreign viruses and plasmids [132–135]. Each crRNA is packaged into a
surveillance complex to protect the intracellular environment from in-
vading viruses and plasmids. crRNA recognizes and mediates the de-
struction of foreign DNA sequences through complex formation with
CRISPR-associated (Cas)protein thatharborsnucleaseactivity [130–132,
136]. Cas proteins are encoded by Cas genes and are localized in the vi-
cinity of a CRISPR locus. The cleavage capability of Cas protein 9 (Cas9)
was demonstrated on plasmid DNA containing a protospacer sequence
and a protospacer adjacent motif (PAM) sequence, however, the addi-
tion of mature crRNA and a trans-activating crRNA (tracrRNA) are es-
sential for proper cleavage. TracrRNA enhances crRNA binding to the
complementary DNA strand and thereby activates crRNA-guided
double-strand DNA (dsDNA) cleavage by Cas9 (Fig. 3A) (detailed de-
scription of the CRISPR/Cas system in bacteria and archaea has been re-
ported in [130,132]). Cleavage is site-speciﬁc and occurs 3 base pairs
upstream (arrows in Fig. 3A) of the PAM sequence. PAM is a very short
stretch of conserved nucleotides in the immediate proximity of the
protospacer, and is a determining factor in self versus non-self recogni-
tion. Engineering of a crRNA:tracrRNA chimera in the presence of Cas9
was sufﬁcient to cleave a plasmid containing the GFP coding sequence
in vitro [132]. Heterologous expression of a codon-optimized
S. pyogenes Cas9 (SpCas9) nuclease, a designed tracrRNA and pre-
crRNAhave been shown to induceprecise RNA-guided cleavage at geno-
mic loci in human andmouse cells [25]. Similarly, targeted modiﬁcation
of loci with SpCas9 and a fusion transcript of crRNA-tracrRNA, also
known as a guide RNA (gRNA), was successful in human and iPS cells
[137,138] (Fig. 3B). A mutation in the RuvC I domain of SpCas9 converts
it into a DNA nickase. DNA nickases introduces only a single-strand
break or “nick” instead of a DSB, which facilitates homology directed re-
pair with high ﬁdelity [25,137].
CRISPR technology offers the ability to edit different loci simulta-
neously or to generate large deletions in mammalian genomes [25,137]. Co-injection into zygotes of Tet1 and Tet2 sgRNA with Cas9
mRNA resulted in mice carrying bi-allelic mutations in both genes
with high efﬁciency and speciﬁcity [139]. The CRISPR/Cas system has
been applied to modify single and/or multiple genes by either NHEJ-
or HDR-mediated repair in numerous model organisms, including
zebraﬁsh [97,140–143], Drosophila [144–146], rats [147–149], mice
[139,147,150–155] and cynomolgus monkeys [156]. Furthermore, co-
injection into zygotes of Cas9 mRNA, various gRNAs and DNA vectors
of different sizes encoding a tag or ﬂuorescent reporter construct result-
ed in mice carrying small insertions or reporter genes. Likewise, using
CRISPR/Cas together with a DNA repair template has been successful
in creating a conditional ﬂoxed allele in mice [157].
Although analysis of potential off-target sites of ﬁve gRNAs in gene-
modiﬁed mice and mouse ES cells identiﬁed off-target mutations with
low frequency [157], the risk for off-target cleavage by CRISPR/Cas has
become an important discussion point, especially since multiple mis-
matches are tolerated by the CRISPR/Cas system [158–160]. These off-
target mutations, even in off-target sites harboring up to 5 mismatches,
were often located within coding genes [158,161]. Yet, the accepted
mismatch depends on the position of the gRNA-DNA interface, e.g.
Cas9-mediated cleavage appears abolished when a single mismatch is
present in the last 10–12 nucleotides near the 3’ end of the gRNA-
target site [25,132]. Off-target modiﬁcations have been observed in
genes with strong homology. The CRISPR/Cas system targeting the
hemoglobin β and CCR5 genes revealed signiﬁcant off-target cleavage
in the related hemoglobin δ and CCR2 genes in human cells, respectively
[162]. Off-targetmodiﬁcations can beminimized by titration of the Cas9
and gRNA dosage and careful design of the gRNA [159,161]. Further-
more, both gRNA structure and composition can inﬂuence RNA-guide
cleavage and diminish off-target mutagenesis [163]. Truncated gRNAs
with shorter regions of complementarity can be used to reduce unde-
sired off-target modiﬁcations and maintain similar on-target genome
editing efﬁciencies [164]. Another method makes use of a Cas nickase
instead of a nuclease. The advantage of this approach is that single-
strand nicks in off-target sites are favorably repaired by the high-
ﬁdelity base excision repair pathway [165]. Cas nickases directed by a
pair of gRNAs targeting opposite strands of a target locus can efﬁciently
mediate DSBs while signiﬁcantly reducing off-target activity in human
cells [160,163,166,167]. In addition, utilization of double nicking has en-
abled highly efﬁcient NHEJ-mediated DNA insertion, HDR and genomic
microdeletions in human cells and mouse zygotes [167]. However, re-
cent studies have demonstrated that single monomeric nickases can in-
duce unwanted indel mutations as well [160,163,164]. Elucidation of
the crystal structure of Cas9, either without or with binding to gRNAs
and DNA, will enhance the functional understanding of Cas9 activity
and possibly lead to increased speciﬁcity [168–170]. Fortunately, a
free web-based application is available to facilitate CRISPR/Cas9-
mediated mammalian genome engineering; it allows users to select
and validate target sequences and identify potential off-target effects
[159,171,172].
6. Concluding remarks
Nuclease technology for genomemodiﬁcation has brought a number
of major advantages in comparison with conventional gene targeting
by homologous recombination in mouse ES cells. The efﬁciency of
nuclease-mediated genome editing is signiﬁcantly higher, as demon-
strated in a number of model organisms, and cell lines from different
species. Nuclease technology can drastically reduce the time line to gen-
erate mutantmice. Direct injection of ZFNs, TALENmRNA or gRNAwith
Cas9 into fertilized mouse oocytes can produce targeted mutations in
founder animals with high efﬁcacy. Most founder lines have subse-
quently been able to transmit the mutated alleles through the germline
to their offspring. These approaches avoid the use of ES cells and the
construction of large targeting constructs, which are laborious proce-
dures. As demonstrated with the CRISPR/Cas system, multiple genes
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Fig. 3.Mechanism of the CRISPR/Cas system. A. Destruction of foreign DNA sequences. Upon challenge with viruses and plasmids, crRNAs recognize and bind to the protospacer sequence
of foreign DNA with an adjacent PAM sequence. TracrRNA improves crRNA binding to the corresponding DNA sequence and thereby triggers crRNA directed double-strand cleavage
through association with the Cas9 nuclease. Double-strand cleavage is site-speciﬁc and occurs 3 base pairs upstream of the PAM sequence, as indicated with the black arrows. B. Genome
editing through the CRISPR/Cas system. A designed gRNA (chimera of crRNA and tracrRNA) recognizes the target sequence in the genomic DNA with adjacent PAM sequence, mediating
the activation of Cas9 through complex formation and induction of a target-speciﬁc DSB. The subsequent DNA repair can then be exploited for editing the genome.
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crossing of single knockout animals [139]. In addition, nuclease technol-
ogy has demonstrated the ability to producemice carrying targeted dis-
ruptions and insertions into two genes located on the Y-chromosome
[106], which was previously not possible. Conventional gene targeting
by homologous recombination has mainly been successful in mouse
ES cells, however nuclease technology can now be applied in a number
of model organisms, including Drosophila, zebraﬁsh, rat and pig [24,27].
Furthermore, nuclease technology can be applied in all genetic back-
grounds, avoiding the need for extensive back crossing [23,41].
Since its discovery, TALENs has quickly overtaken ZFN technology
due to its higher efﬁciency in target sequence cleavage, the develop-
ment of easier and quicker construction methods for TALENs, and a
greater ﬂexibility to target speciﬁc sequences [124,126,173]. Similarly,
the emergence of CRISPR/Cas system has demonstrated a remarkably
high efﬁciency in making speciﬁc genetic modiﬁcations in mammalian
cells and zygotes [25,137,139]. Excitingly, CRISPR can contain multiple
gRNAs that enable simultaneous targeting of multiple genes in mice
and othermodel organisms [139,143,147,149,153]. The design and pro-
duction of gRNAs can be done quickly and easily through in vitrotranscription of double-stranded oligonucleotides or by cloning of oligo-
nucleotides in expression vectors, which is a clear advantage over the
generation of ZFNs and TALENs [25,137]. However, the CRISPR/Cas sys-
tem contains two major pitfalls, namely the requirement of a PAM se-
quence adjacent to the 3’-end of the target sequence and the high
frequency of off-target cleavage [135,158–161]. The requirement of a
PAM sequence limits the number of speciﬁc target sequences. CRISPR/
Cas has utilized two Cas9 proteins derived from S. pyogenes or
S. thermophiles, but recent exploitation of Cas9 orthologs from other
species that recognize different PAM sequences will increase the ﬂexi-
bility in genome editing [135,174–177]. A typical TALEN target se-
quence usually contains around 30 nt that is unique within the mouse
genome, while CRISPR/Cas allows multiple mismatches in the guide se-
quence and therefore increases the likelihood of off-target effects [178].
A possible solution is the use of Cas nickases guided by a pair of gRNAs
targeting opposite strands for genome editing, as this signiﬁcantly re-
duces off-target effects [160,163,167]. In addition, the use of DNA
nickases can partially shift the balance from NHEJ towards HDR-
mediated repair and thereby increase the efﬁciency of gene addition
and gene correction [166].
1948 T. Wijshake et al. / Biochimica et Biophysica Acta 1842 (2014) 1942–1950The emergence of nuclease-mediated genome editing holds great
promise for future use in targeted mouse genome editing technology.
The ease of design, construction, high efﬁciency, potential applications,
and short generation time of mutant micemake nuclease-mediated ge-
nome modiﬁcations a very interesting tool for studying the function of
candidate genes, putative trans- and cis-regulatory elements, and tran-
scriptional factor binding site relevancy in the etiology of human
diseases.
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